Until recently, most humans identified with WNV infection presented with symptoms of WNV fever or meningoencephalitis. By the time symptoms appear, viremia has typically cleared and immune responses evolved, making it difficult to accurately characterize the clinical spectrum of infection or study the interplay between the virus and the immune system. This situation changed dramatically when WNV RNA screening of blood donors using nucleic acid amplification tests (NAT) was implemented in the U.S. in mid-2003. NAT screening will allow characterization of the dynamics of acute viremia and time course of immune responses in primary WNV infection. Prospective enrollment of viremic, pre-seroconversion donors and detailed clinical, virologic and immunologic studies will better define the natural history of infection and the viral and host factors that correlate with control of viremia and varied WNV disease syndromes. We will draw our samples from a unique cohort of viremic individuals detected by the American Red Cross (ARC) and Blood Systems (BSI) networks of blood banks, which together collect approximately 60% of the U.S. blood supply. Medical staff at ARC and BSI will administer interviews (developed in collaboration with CDC) to ascertain the rates of development and severity of WNV-symptom complexes. A subset of viremic donors who develop severe symptomatic infections and matched asymptomatic controls, will be enrolled into a substudy. We will perform virologic and immunologic analyses of frequent sequential samples to characterize the kinetics of primary viremia and the time course of WNV-specific IgM, IgA, IgG and plaque neutralizing antibody seroconversion. Detailed studies of T cell responses, including kinetics and antigen specificity, and of cytokine perturbations will be carried out on the same cases. The findings from these studies will therefore address key blood safety issues and contribute to our understanding of the natural history and pathogenesis of WNV infection by identifying viral and humoral immune parameters that correlate with control of viremia.
| Kaidarova, Zhanna; Bravo, Marjorie D; Kamel, Hany T et al. (2016) Blood group A and D negativity are associated with symptomatic West Nile virus infection. Transfusion 56:1699-706 |
| Carson, Paul J; Prince, Harry E; Biggerstaff, Brad J et al. (2014) Characteristics of antibody responses in West Nile virus-seropositive blood donors. J Clin Microbiol 52:57-60 |
| Petersen, L R; Carson, P J; Biggerstaff, B J et al. (2013) Estimated cumulative incidence of West Nile virus infection in US adults, 1999-2010. Epidemiol Infect 141:591-5 |
| Pybus, Oliver G; Suchard, Marc A; Lemey, Philippe et al. (2012) Unifying the spatial epidemiology and molecular evolution of emerging epidemics. Proc Natl Acad Sci U S A 109:15066-71 |
| Carson, Paul J; Borchardt, Stephanie M; Custer, Brian et al. (2012) Neuroinvasive disease and West Nile virus infection, North Dakota, USA, 1999-2008. Emerg Infect Dis 18:684-6 |
| Tobler, Leslie H; Cameron, Mark J; Lanteri, Marion C et al. (2008) Interferon and interferon-induced chemokine expression is associated with control of acute viremia in West Nile virus-infected blood donors. J Infect Dis 198:979-83 |
| Busch, Michael P; Kleinman, Steven H; Tobler, Leslie H et al. (2008) Virus and antibody dynamics in acute west nile virus infection. J Infect Dis 198:984-93 |
| Prince, Harry E; Lape-Nixon, Mary; Yeh, Cindy et al. (2008) Persistence of antibodies to West Nile virus nonstructural protein 5. J Clin Virol 43:102-6 |
